CymaBay Therapeutics Inc. (NASDAQ:CBAY) is scheduled to announce its earnings results after the market closes on Thursday, August 10th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter.

CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Thursday, May 11th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. The firm had revenue of $4.79 million during the quarter. On average, analysts expect CymaBay Therapeutics to post $-0.64 EPS for the current fiscal year and $-0.62 EPS for the next fiscal year.

Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) traded down 0.56% during midday trading on Tuesday, hitting $7.12. The company’s stock had a trading volume of 43,974 shares. The firm has a 50-day moving average of $6.05 and a 200 day moving average of $4.13. CymaBay Therapeutics Inc. has a 12-month low of $1.15 and a 12-month high of $8.29. The firm’s market cap is $204.71 million.

CBAY has been the topic of several recent research reports. Ifs Securities restated a “strong-buy” rating on shares of CymaBay Therapeutics in a research report on Monday, July 17th. Piper Jaffray Companies set a $7.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research report on Monday, July 17th. Citigroup Inc. restated an “outperform” rating and issued a $15.00 price target (up previously from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Oppenheimer Holdings, Inc. boosted their price target on CymaBay Therapeutics from $8.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, July 20th. Finally, CIBC restated an “outperform” rating and issued a $15.00 price target (up previously from $8.00) on shares of CymaBay Therapeutics in a research report on Thursday, July 20th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $11.88.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/08/cymabay-therapeutics-inc-cbay-set-to-announce-quarterly-earnings-on-thursday.html.

In other CymaBay Therapeutics news, insider Sujal Shah acquired 10,000 shares of the stock in a transaction on Thursday, July 20th. The shares were bought at an average price of $7.34 per share, with a total value of $73,400.00. Following the acquisition, the insider now owns 75,891 shares of the company’s stock, valued at $557,039.94. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Charles Mcwherter acquired 5,000 shares of the stock in a transaction on Thursday, July 20th. The stock was acquired at an average cost of $7.43 per share, for a total transaction of $37,150.00. Following the acquisition, the senior vice president now directly owns 5,100 shares in the company, valued at approximately $37,893. The disclosure for this purchase can be found here. Insiders acquired a total of 20,000 shares of company stock worth $144,750 in the last ninety days. 15.10% of the stock is owned by corporate insiders.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Earnings History for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.